Shares of Supernus Pharmaceuticals Inc. (NASDAQ:SUPN) rose 2.5% on Monday . The stock traded as high as $21.60 and last traded at $21.55, with a volume of 297,421 shares traded. The stock had previously closed at $21.03.

SUPN has been the subject of several recent analyst reports. Zacks Investment Research upgraded Supernus Pharmaceuticals from a “hold” rating to a “buy” rating and set a $23.00 price objective for the company in a research report on Wednesday, July 6th. Piper Jaffray Cos. downgraded Supernus Pharmaceuticals from an “overweight” rating to a “neutral” rating and set a $23.00 price objective for the company. in a research report on Monday, July 18th. Northland Securities downgraded Supernus Pharmaceuticals from an “outperform” rating to a “market perform” rating and set a $24.00 price objective for the company. in a research report on Monday, July 18th. TheStreet upgraded Supernus Pharmaceuticals from a “hold” rating to a “buy” rating in a research report on Tuesday, March 29th. Finally, Jefferies Group restated a “buy” rating and set a $23.00 price objective (up from $19.00) on shares of Supernus Pharmaceuticals in a research report on Thursday, May 12th. Two investment analysts have rated the stock with a hold rating and three have assigned a buy rating to the company. The company currently has an average rating of “Buy” and an average price target of $23.25.

The stock has a market capitalization of $1.06 billion and a PE ratio of 63.61. The company’s 50-day moving average is $19.98 and its 200-day moving average is $16.19.

Supernus Pharmaceuticals (NASDAQ:SUPN) last announced its earnings results on Tuesday, May 3rd. The specialty pharmaceutical company reported $0.08 earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of $0.09 by $0.01. The business earned $43 million during the quarter, compared to analyst estimates of $45.33 million. During the same period in the previous year, the business earned $0.02 EPS. Supernus Pharmaceuticals’s revenue for the quarter was up 53.0% on a year-over-year basis. Analysts anticipate that Supernus Pharmaceuticals Inc. will post $0.63 EPS for the current fiscal year.

In other Supernus Pharmaceuticals news, CFO Gregory S. Patrick sold 3,395 shares of the business’s stock in a transaction that occurred on Thursday, July 14th. The stock was sold at an average price of $22.00, for a total transaction of $74,690.00. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website.

Several hedge funds and institutional investors have made changes to their positions in SUPN. Whitebox Advisors LLC acquired a new position in shares of Supernus Pharmaceuticals during the fourth quarter valued at about $1,014,000. Cornerstone Capital Management Holdings LLC. raised its position in shares of Supernus Pharmaceuticals by 15.2% in the fourth quarter. Cornerstone Capital Management Holdings LLC. now owns 123,600 shares of the specialty pharmaceutical company’s stock valued at $1,662,000 after buying an additional 16,300 shares during the period. Marshall Wace LLP acquired a new position in shares of Supernus Pharmaceuticals during the fourth quarter valued at about $2,345,000. New York State Common Retirement Fund raised its position in shares of Supernus Pharmaceuticals by 3.7% in the fourth quarter. New York State Common Retirement Fund now owns 205,981 shares of the specialty pharmaceutical company’s stock valued at $2,768,000 after buying an additional 7,299 shares during the period. Finally, Sei Investments Co. raised its position in shares of Supernus Pharmaceuticals by 55.3% in the fourth quarter. Sei Investments Co. now owns 212,393 shares of the specialty pharmaceutical company’s stock valued at $2,854,000 after buying an additional 75,673 shares during the period.

Supernus Pharmaceuticals, Inc is a pharmaceutical company focused on developing and commercializing products for the treatment of central nervous system (CNS) diseases. The Company offers products for the treatment of epilepsy, which include extended-release oxcarbazepine (Oxtellar XR) and extended-release topiramate (Trokendi XR).

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.